Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer, GSK And Purdue Will Implement RFID Pilot Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer will initiate a year-long, anti-counterfeiting pilot program for Viagra using radiofrequency identification technology in 2005

You may also be interested in...



FDA Developing "Stronger" Radio Frequency ID Guidance For Drug Tracking

FDA Acting Commissioner Crawford says there will be an update on the RFID guidance "about mid-year." The document will "urge in even stronger terms the wide use of this technology." Crawford believes the U.S. is behind EU countries in adopting RFID for tracking drugs.

FDA Developing "Stronger" Radio Frequency ID Guidance For Drug Tracking

FDA Acting Commissioner Crawford says there will be an update on the RFID guidance "about mid-year." The document will "urge in even stronger terms the wide use of this technology." Crawford believes the U.S. is behind EU countries in adopting RFID for tracking drugs.

FDA Anticounterfeiting Technology Guide Aims To Speed Industry Adoption

Agency will exercise enforcement discretion on labeling and GMP regulations that are triggered by radio frequency identification technology. FDA is working with EPC Global to establish standards of electronic pedigree.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel